Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 26.750- for the period, compared to the consensus earnings per share estimate of 26.910. The company issued revenue guidance of -.

Elevance Health Stock Performance

NYSE:ELV opened at $403.74 on Friday. The stock has a fifty day moving average price of $366.62 and a 200-day moving average price of $344.86. The company has a market cap of $87.68 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 2.26 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $426.98.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts anticipate that Elevance Health will post 26.93 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Ratings Changes

ELV has been the subject of several recent research reports. Evercore reissued a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. JPMorgan Chase & Co. increased their price target on Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Sanford C. Bernstein increased their price target on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday, April 24th. Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and increased their price target for the company from $363.00 to $498.00 in a research note on Wednesday, May 20th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $416.11.

Insider Buying and Selling

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Elevance Health

Hedge funds have recently bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new stake in Elevance Health during the fourth quarter worth $31,000. J.Safra Asset Management Corp bought a new stake in Elevance Health during the fourth quarter worth $32,000. Jessup Wealth Management Inc bought a new stake in Elevance Health during the fourth quarter worth $45,000. Garton & Associates Financial Advisors LLC bought a new stake in Elevance Health during the fourth quarter worth $50,000. Finally, Rossby Financial LCC lifted its holdings in Elevance Health by 85.7% during the fourth quarter. Rossby Financial LCC now owns 156 shares of the company’s stock worth $55,000 after acquiring an additional 72 shares during the period. 89.24% of the stock is currently owned by institutional investors.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.